دورية أكاديمية
أعرض في EDS

Loss of RBM45 inhibits breast cancer progression by reducing the SUMOylation of IRF7 to promote IFNB1 transcription.

التفاصيل البيبلوغرافية
العنوان: Loss of RBM45 inhibits breast cancer progression by reducing the SUMOylation of IRF7 to promote IFNB1 transcription.
المؤلفون: Lv Y; Department of Oncology of the Second Affiliated Hospital of Dalian Medical University & Institute of Cancer Stem Cell, Dalian Medical University, Dalian, 116023, China., Sun S; Department of Oncology & Sino-US Research Center for Cancer Translational Medicine, The Second Affiliated Hospital, Dalian Medical University, Dalian, 116023, China., Zhang J; Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China., Wang C; Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China., Chen C; Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China., Zhang Q; Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China., Zhao J; Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China., Qi Y; Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China., Zhang W; Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China. Electronic address: zhangwj@dmu.edu.cn., Wang Y; Sino-US Research Center for Cancer Translational Medicine of the Second Affiliated Hospital of Dalian Medical University & Institute of Cancer Stem Cell, Dalian Medical University, Dalian, 116023, China. Electronic address: yangwang@dmu.edu.cn., Li M; Department of Oncology & Sino-US Research Center for Cancer Translational Medicine, The Second Affiliated Hospital, Dalian Medical University, Dalian, 116023, China. Electronic address: liman126126@163.com.
المصدر: Cancer letters [Cancer Lett] 2024 Aug 01; Vol. 596, pp. 216988. Date of Electronic Publication: 2024 May 24.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7980 (Electronic) Linking ISSN: 03043835 NLM ISO Abbreviation: Cancer Lett Subsets: MEDLINE
أسماء مطبوعة: Publication: Limerick : Elsevier Science Ireland
Original Publication: Amsterdam, Elsevier/North-Holland.
مواضيع طبية MeSH: Breast Neoplasms*/genetics , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Sumoylation* , RNA-Binding Proteins*/genetics , RNA-Binding Proteins*/metabolism , Interferon Regulatory Factor-7*/genetics , Interferon Regulatory Factor-7*/metabolism , Disease Progression* , Gene Expression Regulation, Neoplastic*, Humans ; Female ; Animals ; Mice ; Transcription, Genetic ; Cell Line, Tumor ; Interferon-beta/metabolism ; Interferon-beta/genetics ; Signal Transduction ; Mice, Nude ; Cell Proliferation ; Tripartite Motif-Containing Protein 28/metabolism ; Tripartite Motif-Containing Protein 28/genetics ; Xenograft Model Antitumor Assays ; Mice, Inbred BALB C
مستخلص: Type I interferons exhibit anti-proliferative and anti-cancer activities, but their detailed regulatory mechanisms in cancer have not been fully elucidated yet. RNA binding proteins are master orchestrators of gene regulation, which are closely related to tumor progression. Here we show that the upregulated RNA binding protein RBM45 correlates with poor prognosis in breast cancer. Depletion of RBM45 suppresses breast cancer progression both in cultured cells and xenograft mouse models. Mechanistically, RBM45 ablation inhibits breast cancer progression through regulating type I interferon signaling, particularly by elevating IFN-β production. Importantly, RBM45 recruits TRIM28 to IRF7 and stimulates its SUMOylation, thereby repressing IFNB1 transcription. Loss of RBM45 reduced the SUMOylation of IRF7 by reducing the interaction between TRIM28 and IRF7 to promote IFNB1 transcription, leading to the inhibition of breast cancer progression. Taken together, our finding uncovers a vital role of RBM45 in modulating type I interferon signaling and cancer aggressive progression, implicating RBM45 as a potential therapeutic target in breast cancer.
Competing Interests: Declaration of competing interest The authors declare no competing interests.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
فهرسة مساهمة: Keywords: Breast cancer; IFNB1; IRF7; RBM45; SUMOylation
المشرفين على المادة: 0 (RNA-Binding Proteins)
0 (Interferon Regulatory Factor-7)
0 (IRF7 protein, human)
77238-31-4 (Interferon-beta)
EC 2.3.2.27 (Tripartite Motif-Containing Protein 28)
تواريخ الأحداث: Date Created: 20240526 Date Completed: 20240616 Latest Revision: 20240701
رمز التحديث: 20240701
DOI: 10.1016/j.canlet.2024.216988
PMID: 38797234
قاعدة البيانات: MEDLINE
الوصف
تدمد:1872-7980
DOI:10.1016/j.canlet.2024.216988